Reshma Kewalramani - 06 Aug 2025 Form 4 Insider Report for VERTEX PHARMACEUTICALS INC / MA (VRTX)

Role: CEO & President, Director
Signature: /s/ Christiana Stevenson, Attorney-in-Fact
Issuer symbol: VRTX
Transactions as of: 06 Aug 2025
Net transactions value: +$3,895,768
Form type: 4
Filing time: 07 Aug 2025, 16:23:31 UTC
Previous filing: 28 Feb 2025
Next filing: 26 Jan 2026
SEC: View on sec.gov

Reporting Owners (1)

Name	Relationship	Address	Signature	Signature date	CIK
Kewalramani Reshma	CEO & President, Director	C/O VERTEX PHARMACEUTICALS INCORPORATED, 50 NORTHERN AVENUE, BOSTON	/s/ Christiana Stevenson, Attorney-in-Fact	07 Aug 2025	0001735944

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	VRTX	Common Stock	Purchase	$1,669,153	+4,290	+4%	$389.08	110,258	06 Aug 2025	Direct	F1, F2
transaction	VRTX	Common Stock	Purchase	$2,226,614	+5,710	+5.2%	$389.95	115,968	06 Aug 2025	Direct	F2, F3

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	Open market purchases reported on this line occurred at a weighted average price of $389.08 (range $388.71 to $389.43).
F2	Dr. Kewalramani undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares purchased at each separate price.
F3	Open market purchases reported on this line occurred at a weighted average price of $389.95 (range $389.72 to $390.53).